A mechanism-based pharmacokinetic-pharmacodynamic (PK/PD) model was developed for exendin-4 to account for receptor-mediated endocytosis via GLP-1 receptor (GLP-1R) as the primary mechanism for its nonlinear disposition. Time profiles of exendin-4 concentrations following intravenous (iv), subcutaneous (sc) and continuous iv infusion doses in rats, iv and sc doses in monkeys, and iv infusion and sc doses in man were examined. Mean data for glucose and insulin after glucose challenges during exendin-4 treatment in healthy rats were analyzed. The PK model components included receptor binding, subsequent internalization and degradation, non-specific tissue distribution, and linear first-order elimination from plasma. The absorption rate constant (k a ) decreased with increasing doses in all three species. The clearance from central compartment (CL c ) (rats: 3.62 ml/min, monkeys: 2.39 ml/min/kg, man: 1.48 ml/min/kg) was similar to reported renal clearances. Selected PK parameters (CL c , V c and k off ) correlated allometrically with body weight. The equilibrium dissociation constant (K D ) was within the reported range in rats (0.74 nM), while the value in monkeys (0.12 pM) was much lower than in man (1.38 nM). The effects of exendin-4 on the glucose-insulin system were described by a feedback model with a biphasic effect equation driven by free exendin-4 concentrations. Our generalized nonlinear PK/PD model for exendin-4 taking into account of drug binding to GLP-1R well described PK profiles following various routes of administration over a large range of doses in three species along with PD responses in healthy rats. The present model closely reflects underlying mechanisms of disposition and dynamics of exendin-4.
DMD #42291 INTRODUCTION
Exendin-4 is a 39 amino acid glucagon-like peptide-1 (GLP-1) analog, sharing approximately 53% sequence identity with mammalian GLP-1 (Doyle and Egan, 2007) .
Exendin-4 binds to pancreatic GLP-1 receptors (GLP-1R) to exhibit anti-diabetic actions, including glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, slowing of gastric emptying, satiety, and, in preclinical models, protection of beta-cells. In addition to the pancreas, GLP-1 receptors are also expressed in various tissues such as brain, lung and kidneys (Korner et al., 2007) .
The disposition of exendin-4 in man has been reported as linear over the therapeutic dose range from 5 to 10 ug (Cvetkovic and Plosker, 2007) . However, the pharmacokinetics (PK) of exendin-4 was reported as nonlinear in monkeys (Ai et al., 2008) . In addition, the Bateman function could not describe the concentration-time profiles over certain ranges of doses in rats with one set of elimination parameter values (Gedulin et al., 2008) , suggesting that the PK in rats may also be nonlinear.
Furthermore, the simple Bateman function does not well represent the underlying mechanism of exendin-4 disposition, such as receptor binding and internalization. The major route of exendin-4 elimination was suggested to be glomerular filtration with subsequent enzyme degradation (Copley et al., 2006) . But in rats with kidneys surgically removed, exendin-4 slowly disappeared from the system , indicating the existence of non-renal clearance. As GLP-1R exist in various tissues and after binding to exendin-4, exendin-4-GLP-1R complexes are internalized and targeted for further degradation, we reasoned that receptor-mediated endocytosis and DMD #42291 degradation may be responsible for the non-renal clearance and the observed nonlinear behavior of exendin-4.
A general model for drugs exhibiting target-mediated drug disposition (TMDD) exists (Mager and Jusko, 2001) . After administration, drug can be distributed to the peripheral compartment, directly eliminated, or bind to receptors. The drug-receptor complexes can be eliminated or dissociated to free receptors. The TMDD model uses receptor binding and receptor-mediated endocytosis as the primary mechanism of nonlinear drug disposition. Recently, we successfully captured the disposition of exendin-4 in diabetic rats using the TMDD model (Gao and Jusko, 2011) . However, the PK of exendin-4 in other species has not been assessed using mechanistic modeling.
Generally, the in vivo pharmacological effects of exendin-4 have been evaluated either qualitatively or by comparing empirical measures such as the area under the plasma glucose and insulin concentration-time curves. Mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) models can provide improved insights into drug actions. Mager et al characterized the effects of exendin-4 on glucose-insulin homeostasis under hyperglycemic clamping with a mechanism-based PD model, but used a hypothetical linear PK function (Mager et al., 2004) .
We sought to carefully analyze exendin-4 disposition and effects using a mechanism-based PK/PD modeling approach in various species. This report characterizes the disposition of exendin-4 following doses of intravenous (iv), subcutaneous (sc) or iv infusion in rats, monkeys, and man using a TMDD PK/PD model to describe the insulintropic effects of exendin-4.
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METHODS
The time profiles of exendin-4 concentrations in rats and man were obtained from studies conducted by Amylin Pharmaceuticals, Inc. The mean concentrations of exendin-4 in monkeys were captured by computer digitization from a publication (Ai et al., 2008) . For the model fittings, all concentration data were converted to pmol/L units, and drug doses were converted to total moles using the molecular weight of exendin-4 of 4186.6.
In the rat PK study, male Sprague-Dawley (SD) rats (body weight 350-370 g, n = 4-7) received exendin-4 via three different routes -iv, continuous iv infusion, and sc bolus -at three doses: 0.5, 5, and 50 nmol (bolus injection), and at 0.5, 5, and 50 nmol/hr (iv infusion). Samples were assayed using a two-site sandwich assay developed at Amylin Pharmaceuticals, Inc. The minimum detectable concentration of exendin-4 was 15 pmol/L.
In another study, male SD rats (body weight 380-420 g, n = 4-8) were infused iv using the same volume of saline or exendin-4 at 3, 30, 300, and 3000 pmol/kg/min for 2 hours. At 30 min after beginning the infusion, D-glucose (5.7 mmol/kg) was injected iv at a rate of 0.5 ml/min over 2 to 3 min. Plasma glucose was determined by immobilized oxidase chemistry on an YSI 2300 Stat Plus, and insulin was determined by radioimmunoassay (Linco Research, St Charles, MO).
In the monkey PK study (Ai et al., 2008) , male rhesus monkeys (body weight 4.3 ± 0.7 kg, n = 3) were given either a single sc injection of 1, 3, 10 μ g/kg, or a single iv injection of 3 μ g/kg. Serum exendin-4 concentrations were measured using a
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radioimmunoassay. The linear range of this assay was 25-2000 pg/ml and the limit of quantitation of was 25 pg/mL.
Data from three human studies were included in the current analysis. In study A (Kolterman et al., 2005) , 8 subjects (body weight 88.5 ± 9.4 kg) received 0.1, 0.2, 0.3, or 0.4 μ g/kg sc doses of exendin-4. In study B (Kolterman et al., 2005) 
Pharmacokinetic model
For initial data evaluation, mean profiles of exendin-4 for each iv dose obtained from rats were used to perform a noncompartmental analysis (NCA) and curve fitting to a biexponential equation (C = C 1 ·e −λ1·t +C 2 ·e −λ2·t ) using WinNonlin 5.0 (Pharsight Corp., NC) to evaluate dose-dependent changes in clearance (CL), steady-state volume of distribution (V ss ), and distributional clearance (CL D ).
For the next stage, a mechanism-based modeling approach was used for data analysis. The general scheme of the applied PK/PD model is presented in Figure 1 . The free exendin-4 (C) in plasma can bind to GLP-1R (R) with a second-order rate constant (k on ) to form drug-receptor complex (RC), distribute to and from tissues (A T ) by firstorder rates (k pt and k tp ), and be directly eliminated (k el ). The RC can dissociate at a firstorder rate (k off ) and be internalized and degraded (k int ). The GLP-1R (R) is assumed to remain constant (R tot ). The TMDD PK model can be described by:
where V C represents the volume of the free exendin-4 (central) compartment.
The input function for Eq.1 following sc doses is:
where k a is the first-order absorption rate constant and F is the absolute bioavailability after sc doses.
Pharmacodynamic model
The PD model proposed for insulintropic effects of exendin-4 is shown in Figure   1 . The basic structure, the feedback model, represents the interregulated interaction between glucose and insulin: glucose (Glu) stimulates insulin secretion with a linear stimulation factor S Glu , and insulin (Ins) stimulates glucose uptake with a linear stimulation factor S Ins . The homeostasis of glucose and insulin were described by two indirect response models: k outG and k outI are the first-order output rate constants, and For initial evaluation, the simple feedback model was fitted to all the paired glucose and insulin profiles. All of the parameter estimates were comparable between dose groups, except for parameter S Glu . The next step was to apply the feedback model 
where S max is the maximum stimulation factor of the response; k 1 and k 2 are constants in the Adair function. The baseline condition G b and I b were fixed as the measured predose values.
Using RC as the driving function for the effects of exendin-4 was also tested:
All computer fittings and simulations were done using ADAPT II (BMSR, USC, CA) with the maximum likelihood method. The variance model was
where V i is the variance of the ith data point, 
RESULTS
Pharmacokinetics
The TMDD model has been used to capture the exendin-4 disposition in diabetic rats (Gao and Jusko, 2011) and adequately described exendin-4 PK in rats, monkeys and humans in this report. As shown in the model scheme (Figure 1 ), the TMDD model consists of target-binding (k on , k off ), internalization and degradation of the receptor complex (k int ), non-specific tissue distribution (A T ), and a linear elimination pathway (k el )
from V c .
Rat PK
The mean exendin-4 concentration-time profiles after various doses in rats are shown in Figure In order to detect and properly quantify nonlinearities in PK, a wide range of drug doses is required. In man, disposition of exendin-4 has been described as linear over a narrow dose range, and the nonlinearity might also be hidden by flip-flop kinetics after sc injection. Straightforward evidence of nonlinear kinetics in rats was the lack of doseproportionality of NCA parameters and C ss resulting from continuous infusion (Table 1) .
Early blood sampling is particularly important to capture binding characteristics of drugs with the general TMDD model and concentrations around the K D value are desired. In the rat study, data were available from 5 min after iv bolus dosing and via various administration routes and observed concentrations ranged widely around the K D value.
All parameters were estimated (Table 2 ) with reasonable precision (< 50% except for k off ). The clearance (CL c = k el ·V c ) is 3.62 ml/min, which is very close to the reported renal clearance (3.44 ml/min) ). The equilibrium dissociation
is in the range of the reported values for specific binding of exendin-4 and GLP-1 to normal rat tissues (Goke et al., 1993; Goke et al., 1995; Larsen et al., 1997; Satoh et al., 2000) . The total receptor concentrations (R tot ) was estimated to be 5.21 nmol/L for SD rats. The internalization rate constant was slightly higher than k el . Bioavailability was estimated as close to 1 and then fixed as 1 in the final model. The absorption rate constant in rats decreased with increasing dose.
Monkey PK
This article has not been copyedited and formatted. The final version may differ from this version. The fitted profiles of exendin-4 in monkeys following various iv and sc doses are presented in Figure 3 , and parameter estimates are listed in Table 3 . The model well described monkey PK profiles, and yielded parameter estimates with reasonable CV%, except for parameters related to the drug-receptor complex (k on , k off and k int ). The value of CL c was 2.39 ml/kg/min, within the range of GFR in healthy monkeys (2.2-3.6 ml/kg/min) (Altaian and Dittmer, 1974) . The K D value in monkeys was 0.12 pmol/L, which is 5000-fold lower than estimated in rats. The internalization rate constant in monkeys was 15 times lower than k el . Bioavailability was around 70%, and the absorption rate constant decreased with dose, as observed in rats.
Man PK
The model-predicted time profiles of exendin-4 in three human studies are shown in Figure 4 and parameter estimates are listed in Table 3 . The TMDD model adequately described the PK profiles from the three studies, but was unable to estimate total receptor content (R tot ), thus this parameter was fixed as a computer generalized value of 1.24 nmol/L. This value is 3.2 fold lower than the R tot estimate in rats, which agrees with one observation where rat receptor density in lung and thyroid gland was as 2-5.5-fold of human receptor density (Korner et al., 2007) . Since concentrations only after sc doses and one continuous iv infusion dose were available, it is no surprise that parameters were estimated with generally high CV%, especially for k on , k off and k int . The CL c was 1.48 ml/min/kg, almost identical to GFR in healthy subjects (125 ml/min in a 70 kg man). Bioavailability was fixed as 1 and the absorption rate constants were lower at higher doses as was also found in other species. A population modeling approach with more extensive data would improve these parameter estimates.
This article has not been copyedited and formatted. The final version may differ from this version. 
Pharmacodynamics
Increases of glucose and insulin after glucose challenge during continuous infusion of exendin-4 in rats are shown in Figure 5 . Since no drug concentrations were measured in this study, the drug PK profiles ( Figure 6A ) were simulated according to the TMDD model and parameter values. Exendin-4 almost (>80%) reached steady-state after 30 min of infusion, at which time glucose was injected.
The next step was to evaluate the appropriateness of the feedback model describing the glucose and insulin physiological system in rats. The model reasonably characterized the glucose and insulin profiles, and all parameters, except for S Glu , had similar values between control and other dose groups. Therefore, the feedback model well represents the glucose-insulin system in rats. The initial analysis also showed that drug treatment only affected S Glu , the stimulation factor of glucose on insulin production, which was in agreement with the mechanism of action of exendin-4 on beta cells. Thus, in the next step of modeling, all rats shared the same set of parameters, but S Glu was allowed to change. As shown in Figure 6B , the estimated S Glu values first increased and then decreased with drug concentrations at the time of glucose challenge (C 30min ). The
Adair function (Adair, 1923) was able to characterize the bell-shaped relationship between S Glu and C 30min , and Figure 6B depicts the fitted curve with this function.
The drug-receptor complex (RC) was also tested as the driving force for PD. The model fitted the concentration profiles well, but failed to generate precise parameters (ADAPT II was not able to provide CV% for parameter estimates). In addition, AIC values also favored C as the driving force. On the other hand, the PD study design did not contain enough information to differentiate the driving force of the PD effect, as both C and RC reached apparent steady-states by the time of glucose injection. In addition, in a rat study conducted in our lab, maximum insulin stimulation occurred prior to maximum RC, indicating that the PD effect was better driven by C (Gao and Jusko, 2011 ).
In the final PK/PD model, the plasma concentrations (C) were used to stimulate insulin release (Eq. 7). As shown in Figure 
DISCUSSION
Exendin-4, a potent GLP-1R agonist, exhibits insulintropic effects in a variety of animal models and man. This study, to our knowledge, is the first instance of applying a mechanistic model to quantify the disposition of exendin-4 in various species and the dynamics of exendin-4 in healthy rats. The general TMDD model delineating receptormediated drug disposition was proposed to characterize the nonlinear kinetic behavior across species. The likely mechanism of action was integrated into an existing model of the glucose-insulin system, thereby facilitating the simultaneous analysis of glucose and insulin responses to glucose challenge and drug effects.
Pharmacokinetics
The binding of exendin-4 to GLP-1R can be saturated at high ligand doses which contributes to the saturable clearance of exendin-4, although this has not been experimentally quantified. Recently, we reported that exendin-4 followed TMDD kinetics in Goto-Kakizaki (GK) diabetic rats (Gao and Jusko, 2011) . Generally, the parameter estimates were similar between SD rats (in the current report) and GK rats.
Comparisons of the two rat strains were discussed previously (Gao and Jusko, 2011) .
The primary elimination route of exendin-4 has been proposed as glomerular filtration and k el physiologically represents renal elimination (Copley et al., 2006) . The linear CL c in rats, monkeys and man was very close to reported renal clearances or GFR in healthy species. In rats, the relative contribution of CL c to the total clearance was about 73% at the lowest dose, and nearly 100% at the highest doses. The V c in the three species was larger than plasma (serum in monkeys) volume. Simple allometry was assessed for various parameters. Figure 7 shows the correlation between selected This article has not been copyedited and formatted. The final version may differ from this version. (Widmann et al., 1995) . Our estimated k on was about 4 times lower than these measured values, and k off was identical to the lower value, which resulted in a K D value (0.74 nmol/L) comparable with other literature reports (Goke et al., 1995; Larsen et al., 1997; Satoh et al., 2000) . The internalization half-life was 7 min (Goke et al., 1995) reported the binding sites of exendin-4 on the posterior lobe of rat pituitary as 7.8 pmol/L per gram tissue, similar to our estimates especially considering that other tissues (e.g. islets, intestine) may have higher GLP-1R density (Korner et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. (Goke et al., 1995) . Nevertheless, k on and k off in monkeys and humans are not precisely estimated.
Pharmacodynamics
The PD component of the model reflects the stimulation of insulin secretion by exendin-4. Exendin-4 has to distribute to pancreas and bind to GLP-1R to stimulate insulin release. However, pancreatic GLP-1R is mostly expressed on the surface of the beta cells facing the endothelium (Tornehave et al., 2008) , and distribution would be quite fast and therefore a biophase between plasma and pancreas is unnecessary.
One can argue that exendin-4 stimulates insulin secretion by binding to pancreatic GLP-1R and then initiating receptor-mediated signaling pathways. However, in the final PK/PD model, the plasma concentration (C), rather than drug-receptor complex (RC) was found to work better as the driving force for exendin-4 insulintropic effects. Mathematically, if the effect is driven by C (Eq. 7), the transduction between receptor binding and effect is assumed as linear. If the effect is initiated by RC (Eq. 8),
the transduction between receptor binding and the effect is implied as nonlinear.
This article has not been copyedited and formatted. The final version may differ from this version. Direct evidence supporting Eq. 7 over Eq. 8 came from our observations in GotoKakizaki rats (Gao and Jusko, 2011) . After an iv bolus of exendin-4, insulin peaked before the maximum concentrations of RC. Moreover, since pancreatic GLP-1R are mostly expressed on the surface of the beta cells (Tornehave et al., 2008) , exendin-4 can bind to the receptor quite fast and directly stimulate insulin release. Furthermore, binding in other tissues besides pancreas might account for a large portion of drugreceptor complexes.
The basic structure of the PD model represents the feedback mechanism between glucose and insulin. This model utilizes the most simplistic mechanism and functions adequately in various situations. In general, the final estimated parameters controlling glucose and insulin regulation (Table 4) Other mathematical functions might also describe the bell-shaped dose response relationship, such as a hypothetical antagonist effect generated by exendin-4. But, physiologically, this is not detected in rats, and mathematically, more parameters in the model would lead to over-parameterization. Therefore, the simple Adair function is reasonable for modeling the insulintropic effects of exendin-4.
In conclusion, a mechanistic TMDD PK/PD model was developed that provides quantitative insights into the in vivo PK properties of exendin-4 in various species and the in vivo PD properties in healthy rats. Plasma clearance and volume of distribution followed simple allometric scaling principles across species. The integrated PK/PD model was exemplified using data from healthy rats and well described glucose and This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version.
